The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The study will investigate the efficacy of oral levosimendan in patients with chronic New York Heart Association (NYHA) IIIb-IV heart failure (HF) using a composite end-point evaluating patient symptoms, morbidity and mortality. The patients are on treatment for at least 6 months.
Condition or disease
Chronic Heart FailureHeart Diseases
The patients are randomised to 3 groups; higher or lower levosimendan dose group or placebo.
Effects of Peroral Levosimendan in the Prevention of Further Hospitalisations in Patients With Chronic Heart Failure. A Randomised, Phase II, Double-Blind, Placebo-Controlled, Multi-Centre, Parallel-Group Study
Study Start Date
Estimated Study Completion Date
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Diagnosed chronic heart failure
Severe symptoms (NYHA IIIb-IV)
Optimal on-going oral treatment for HF
Left ventricular ejection fraction less than or equal to 30%
Severe obstruction of ventricular outflow tracts
Acute myocardial infarction within 30 days before screening
Cardiac surgery or coronary angioplasty within 30 days before screening